Identifying, finding and analyzing the component costs of Essential Medicines WHO/HAI Medicine Prices Project.

Slides:



Advertisements
Similar presentations
Groningen: Expert workshop Input-Output tables Valuation matrices in the Finnish supply and use tables. Antti Pasanen September 2005.
Advertisements

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
1 CHAPTER M2 Classifying Costs © 2007 Pearson Custom Publishing.
Regulating Supply Chain Mark-Ups to Control Medicine Prices—A Review of the Literature in Low- and Middle- Income Countries Ball, Douglas
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.
1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.
Chapter 9: Marketing: Providing Value to Customers
1 Generating reliable evidence: measuring medicine prices and availability Dr Richard Laing Department of Essential Medicines and Pharmaceutical Policy.
Lesson 7.6: Markup and Discount
Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United.
Value Added Tax (VAT). Definition of VAT - One of the indirect taxes, which are easily receivable, and achieve high productivity, and do not cause reactions.
Back to Table of Contents
1 WHO/HAI Pricing Policy Papers To assist policy-makers and others, WHO and HAI are developing a series of reviews on pharmaceutical pricing policies and.
Analysis of the Pharmaceutical Supply Chain in Jordan Simon Conesa 1, Prashant Yadav 1, Rania Bader 2 (2009) 1 MIT-Zaragoza International Logistics Program,
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
INTERNATIONAL LOGISTICS Source: International Business (1998). Fifth Edition. Zinkota, M., Ronkainen, I., and Moffett, M. Fort Worth: The Dryden Press.
“LOGISTICS AND SHIPPING” WORKSHOP Presenter: Beverly Johnson June 26, 2015.
Amanullah Saif Cost Accountant, Drug Control Administration Government of Pakistan WHO/HAI Project on Medicine Prices & Availability Cost Plus Price Setting.
Taxes on Medicines Margaret Ewen Coordinator, Global Projects (Pricing) Health Action International (HAI) Amsterdam.
1 CHAPTER XIX PRICING IMPORTED GOODS & DISTRIBUTION CHANNELS  Cost of Imported Merchandise  Value Marketing  Distribution Channel  Selection of Sales.
10-3 Pricing Factors DO NOW: When purchasing an item how do you determine whether the asking price is a good value?
Paying the Price: The Affordability of Medicines Across the Commonwealth (and elsewhere) Margaret Ewen Health Action International.
Section 24.2 Inventory Control
Cost as a Barrier to Access: Identifying the Component Costs of Essential Medicines Levison L,Laing RL.
Data Disclosure: An Ongoing Progress Towards Transparency Abeer Rabayah B.Sc Pharmacy -MBA /Marketing MeTA National Coordinator.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 18 th 2009 Alexandra Cameron, Department of Essential Medicines.
Barriers To International Trade
EXPERIENCES IN SOUTH AFRICA WITH THE INTRODUCTION OF PHARMACEUTICAL PRICING LEGISLATION Zokufa HZ, Pillay T Pharmaceutical Policy and Planning, Department.
Screen 1 of 21 Markets Assessment and Analysis Markets and Food Security LEARNING OBJECTIVES Understand basic market concepts and definitions relevant.
Medicines prices: measurement and findings in countries Richard Laing PSM - WHO Gilles Forte TCM - WHO Margaret Ewen HAI - Europe.
Samia Saad 1, Birgit Kerstens 2, Wilbert Bannenberg 1,2 1 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom; 2 Health Research for Action (HERA),
Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.
Markup and Discount NS 1.4 Calculate given percentages of quantities and solve problems involving discounts at sales, interest earned, and tips. Objective:-Students.
Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Availability of children’s medicines in Africa, 2007 Jane Robertson, Gilles Forte, Suzanne Hill.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Paying the price: Medicine prices, availability and affordability across the globe Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Adhoc Committee on Health 22 June DISPENSING LICENCE  Have 4 providers for the course 1. Health Science Academy 2. Intec College 3. Medunsa 4.
Medicines prices: measurement and findings in countries
Tax, tip, and Markup Notes and examples.
1 Medicine price and availability surveys – methodology essentials – policy options Richard Laing Department of Essential Medicines and Pharmaceutical.
Markups and Markdowns: Perishables and Breakeven Analysis
Medicines Transparency Alliance Presented by Gilles Forte Department of Essential Medicines and Health Products, WHO On behalf of WHO and HAI Technical.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Medicines Transparency Alliance16/12/2015 Pricing: Observations Nazeem Mohamed Chairman, Uganda Pharmaceutical Manufacturers Association (UPMA) C.E.O.
Section % of what number is 75? 2. What percent of 25 is 4? 3. If you buy a shirt that was originally $45 but it is on clearance for 25% off,
ICIUM 2011 Can Accredited Drug Dispensing Outlets (ADDO) Accomplishments be Sustained in Tanzania.
Out-of-pocket and Out-of-reach Margaret Ewen, Coordinator, Global Projects (Pricing) Health Action International Amsterdam.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
Chapter 24 Stock Handling and Inventory Control Section 24.1 The Stock Handling Process Section 24.2 Inventory Control Section 24.1 The Stock Handling.
SB-Lesson 12.1: Markup and Discount Terminology Selling Price - The price retailers charge customers Cost - The price retailers pay to a manufacturer.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, 2012 Richard Laing with materials provided by Alexandra Cameron, Department.
Wilbert Bannenberg & Elodie Brandamir Technical & Operational Directors MeTA International Secretariat MeTA Kyrgyzstan Forum Bishkek, 16 April 2009 Medicines.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
Supply Chain Management Chapter Definition of Supply Chain Management Supply Chain Management refers to the effort to coordinate suppliers, manufacturers,
Lesson 8.3B: Markup and Discount Change each percent into a decimal  5.5%  10.24%  29% .1%  1%  50%  5%    0.29   0.01.
Medicine prices and availability, evidence for policy
Fashion Merchandising
CHAPTER XIX PRICING IMPORTED GOODS & DISTRIBUTION CHANNELS
Channels of Distribution
Markups and Markdowns: Perishables and Breakeven Analysis
Lesson 7.6: Markup and Discount
Supply Chain Management 3B Workshop 1
1 CHAPTER M2 Classifying Costs © 2007 Pearson Custom Publishing.
Net GST payable to the ATO less GST refunds from Purchases
Presentation transcript:

Identifying, finding and analyzing the component costs of Essential Medicines WHO/HAI Medicine Prices Project

Definition: Price components “…in the field of pharmaceuticals … retail prices, in particular, are often a distant relation to manufacturer’s selling price. Import duties, taxes, wholesale markups, both formal and informal, can double the price of a drug between manufacturer and consumer.” (WHO Secretariat 2001)

Retail price = manufacturer’s selling price + insurance & freight + import tariffs + taxes (national, state, local) + import markups + port, customs, inspection charges + wholesale markups + retail markups + local storage and distribution charges + VAT/GST + dispensing fees

Why component costs?  Regularly constitute 30%-45% of retail prices  Known to range to 85% or higher  Many unknowns, many variations among products, sectors & countries  Need to know impact for planning  Use information for price negotiation

Total Mark-up as a Percentage over CIF Price, with Portions Attributable to Different Component Costs Source: Madden 2004

The Price Components Handbook  Expands existing components section in “Medicine Prices”  Presents new methodology, better guidance  Approach: Identify, Find, Analyze

Identifying component costs  “Price Components” provides example components  Ask participants in supply chain  But: many don’t know costs exist Be a detective! Look for large price gaps, and ask questions!

Stages of the supply chain 0manufacturer’s selling price 1+ insurance & freight 2+ import tariffs & taxes + import markups + port, customs, inspection charges 3 + wholesale markups + distribution charges 4+ retail markups + local taxes & distribution charges 5+ VAT/GST + dispensing fees

Finding component costs  Start at retail shop, trace the products “up” supply chain to Supplier  Ask, ask, ask  Check from both sides But many obstacles:  Observed & official markups differ  Middlemen guard cost, markup info  MSP as “confidential information”

Data collection tool: Stage 5 Charge basis : Fee Percent Charge status : Not applicable Not found Unknown Value

Stage 4 Only data collection: “Source” information is just used in tracking

Stage 3

Stage 2

Stage 1

Data collection Drug 1Drug 2Drug 3 Public Private Other

Analyzing component costs  Enter data in Price Component Workbook  Automatically calculates totals Share of component costs across stages

Reports Provides reports on:  MSP vs add-on costs for each drug  Contribution each stage to retail cost  Comparison across drugs by stage  Comparison across sector by stage  Contribution MSP & add-on by stage Contribution of component costs by stages

International comparison  Compare stages, not components  When data not separable, can still be compared A B C D

Current status  Draft “Price Components Handbook” ready for review by project team  Complete coding of Price Components Workbook  Pilot test methodology this spring  Watch for updates on HAI website: